Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 48, 2018 - Issue 12
Submit an article Journal homepage
532
Views
9
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors

Xiaoliang ZhuoDepartments of Pharmaceutical Candidate Optimisation, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA and Correspondence[email protected]
,
Ying-Zi WangDepartments of Pharmaceutical Candidate Optimisation, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA and
,
Kap-Sun YeungDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
Juliang ZhuDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
Xiaohua Stella HuangDepartments of Pharmaceutical Candidate Optimisation, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA and
,
Kyle E. ParcellaDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
Kyle J. EastmanDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
John F. KadowDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
Nicholas A. MeanwellDiscovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
,
Yue-Zhong ShuDepartments of Pharmaceutical Candidate Optimisation, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA and
&
Benjamin M. JohnsonDepartments of Pharmaceutical Candidate Optimisation, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA and
show all
Pages 1215-1226 | Received 08 Oct 2017, Accepted 22 Nov 2017, Published online: 12 Dec 2017

References

  • Abe H, Kikuchi S, Hayakawa K, et al. (2011). Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate). ACS Med Chem Lett 2:320–4
  • Ago H, Adachi T, Yoshida A, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (London, England: 1993) 7:1417–26
  • Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN. (2013). Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metab Dispos 41:422–9
  • Baillie TA, Davis MR. (1993). Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319–25
  • Blanksby SJ, Ellison GB. (2003). Bond dissociation energies of organic molecules. Acc Chem Res 36:255–63
  • Bressanelli S, Tomei L, Roussel A, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96:13034–9
  • De Clercq E. (2007). The design of drugs for HIV and HCV. Nat Rev Drug Discov 6:1001–18
  • de Meijere A. (1979). Bonding properties of cyclopropane and their chemical consequences. Angew Chem 18:809
  • Easterbrook J, Fackett D, Li AP. (2001). A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem Biol Interact 134:243–9
  • Eastman KJ, Parcella K, Yueng K-S, et al. (2017). The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase. Med Chem Commun 8:796–806
  • Fasinu P, Bouic PJ, Rosenkranz B. (2012). Liver-based in vitro technologies for drug biotransformation studies – a review. Curr Drug Metab 13:215–24
  • Guengerich FP. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–50
  • Hirata K, Kotoku M, Seki N, et al. (2016). SAR exploration guided by LE and Fsp(3): discovery of a selective and orally efficacious RORγ inhibitor. ACS Med Chem Lett 7:23–7
  • Howard S. (2009). Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 52:379–88
  • Kvaternick V, Pollmeier M, Fischer J, Hanson PD. (2007). Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. J Vet Pharmacol Ther 30:208–17
  • Lesburg CA, Cable MB, Ferrari E, et al. (1999). Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6:937–43
  • Link JO, Taylor JG, Xu L, et al. (2014). Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57:2033–46
  • Lou Y, Han X, Kuglstatter A, et al. (2015). Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J Med Chem 58:512–16
  • Ma S, Zhu M. (2009). Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem Biol Interact 179:25–37
  • Scola PM, Wang AX, Good AC, et al. (2014). Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57:1708–29
  • Talele TT. (2016). The “Cyclopropyl Fragment is a versatile player that frequently appears in preclinical/clinical drug molecules”. J Med Chem 59:8712–56
  • Tian Z, Fattahi A, Lis L, Kass SR. (2006). Cycloalkane and cycloalkene C–H bond dissociation energies. J Am Chem Soc 128:17087–92
  • Vachharajani NN, Yeleswaram K, Boulton DW. (2003). Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 92:760–72
  • van Leeuwen P, Morokuma K, van Lenthe JH. (1995) Theoretical aspects of homogeneous catalysis: applications of Ab initio molecular orbital theory (catalysis by metal complexes). Dordrecht: Springer
  • Yu KL, Sin N, Civiello RL, et al. (2007). Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett 17:895–901
  • Zhuo X, Huang XS, Degnan AP, et al. (2015). Identification of glutathione conjugates of acetylene-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 43:578–89

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.